A Comprehensive Review Of Approaches In In-Silico Anti-Depressant Drug Discovery

Sweta Rai[1], Prashant Kumar[2], Dheeraj Chitara[3], Prakash Chandra Gupta[1*]

[1]School Of Pharmaceutical Sciences, Chhatrapati Shahu Ji Maharaj University, Kanpur, India

[2]Q-Line Biotech Limited, Lucknow, India

[3]Department Of Biotechnology, School Of Science, Jecrc University, Jaipur, India

***Corresponding Author:**

Dr. Prakash Chandra Gupta

Assistant Professor, School Of Pharmaceutical Sciences

Chhatrapati Shahuji Maharaj University, Kanpur, India

Email: herbalprakash@yahoo.com

Abstract

The relentless pursuit of effective anti-depressant therapies in the realm of psychiatry necessitates innovative approaches to drug discovery, with in-silico methodologies standing at the forefront of this scientific revolution. This comprehensive review aims to elucidate the diverse spectrum of in-silico strategies employed in the identification and development of novel anti-depressant compounds. By systematically examining computational models, molecular docking simulations, pharmacophore mapping, and machine learning algorithms, we highlight the transformative potential these digital techniques offer in predicting drug efficacy, understanding molecular interactions, and optimizing pharmacokinetic and pharmacodynamic properties. Through the integration of quantitative structure-activity relationships (QSAR) and virtual screening processes, our review underscores the efficiency gains and the significant reduction in time and resources compared to traditional experimental methods. Furthermore, we discuss the critical role of bioinformatics and systems biology in uncovering the complex neurobiological pathways involved in depression, thereby facilitating targeted drug design and personalized medicine approaches. By synthesizing current findings and identifying methodological strengths and limitations, this review provides a roadmap for future research directions in the in-silico discovery of anti-depressant drugs, ultimately contributing to the advancement of mental health therapeutics.

Keywords: Depressive Disorder, Pharmaceutical Design, Tailored Healthcare, Receptor Targets, Safety Assessment

How To Cite This Article: Rai S, Kumar P, Chitara D, Gupta PC. A comprehensive review of approaches in in-silico anti-depressant drug discovery. Int J Drug Deliv Technol. 2026;16(9s): 789-796; Doi: 10.25258/Ijddt.16.9s.81

INTRODUCTION

In-silico drug discovery is reshaping the creation of antidepressants, using computational simulations to foresee drug interactions with biological entities, thus expediting the development and refinement of treatments for depression's intricate neurobiology. Depression, marked by enduring sadness and disinterest, represents a significant worldwide health issue, complicated by its diverse origins including genetic, environmental, and psychological components, posing notable hurdles in drug creation [1]. While SSRIs and TCAs have aided many, their limitations such as delayed therapeutic onset and side effects remain concerns [2].

Computational discovery emerges as a viable strategy to surmount these obstacles, employing digital tools to mimic drug-receptor engagements, evaluate compound effectiveness and safety, and unearth new therapeutic targets. This technique considerably diminishes the time and expense linked to drug development's initial phases by filtering compounds more likely to succeed in clinical evaluations [3].

A pivotal use of in-silico methods in antidepressant discovery is finding new targets beyond conventional monoamine routes. Current investigations delve into the roles of neurotrophic elements, inflammatory mediators, and glutamatergic signals in depression, unveiling innovative therapeutic paths [4]. Computational screening, for instance, has pinpointed small molecules that influence brain-derived neurotrophic factor (BDNF), a key player in the neurogenesis and synaptic adaptations associated with depression [5].

Techniques like molecular docking and pharmacophore modeling stand out in in-silico processes, projecting how potential antidepressant molecules might bind to novel targets. These methods facilitate the identification of compounds with supreme binding efficiency and precision, thereby minimizing unintended interactions [6].

TABLE 1. COMPARES VARIOUS TYPES OF DEPRESSION, HIGHLIGHTING KEY CHARACTERISTICS, SYMPTOMS, AND COMMON TREATMENTS ASSOCIATED WITH EACH TYPE

Type of Depression	Key Characteristics	Common Symptoms	Common Treatments	References
Major Depressive Disorder (MDD)	Persistent sadness, lack of interest in activities, significant impairment in daily life.	Sadness, hopelessness, fatigue, changes in appetite, sleep disturbances.	Psychotherapy, antidepressants, lifestyle changes.	[1]
Persistent Depressive Disorder (PDD)	Chronic depressive symptoms lasting for 2 years or more, but less severe than MDD.	Low mood, low self-esteem, lack of energy, changes in appetite and sleep.	Psychotherapy, antidepressants.	[7]
Bipolar Disorder	Extreme mood swings including emotional highs (mania) and lows (depression).	Depressive episodes: Sadness, hopelessness. Manic episodes: High energy, reduced need for sleep, risk-taking behaviors.	Mood stabilizers, psychotherapy.	[8]
Seasonal Affective Disorder (SAD)	Depression that occurs at a specific time of year, usually winter.	Moodiness, fatigue, social withdrawal, changes in sleep and appetite, especially in winter months.	Light therapy, psychotherapy, antidepressants.	[9]
Perinatal Depression	Depression occurring during pregnancy or within 12 months after delivery.	Sadness, anxiety, difficulty bonding with the baby, thoughts of harming oneself or the baby.	Psychotherapy, antidepressants, support groups.	[10]
Premenstrual Dysphoric Disorder (PMDD)	Severe form of PMS with debilitating emotional and physical symptoms.	Mood swings, irritability, depression, anxiety, physical symptoms related to menstrual cycle.	Antidepressants, oral contraceptives, lifestyle changes.	[11]
Psychotic Depression	Severe depression plus psychosis (delusions or hallucinations with depressive themes).	Depressive symptoms plus delusions or hallucinations, often with depressive themes.	Antipsychotic drugs, antidepressants, psychotherapy.	[12]
Atypical Depression	Mood reactivity (mood improves in response to positive events) and specific features.	Significant weight gain, hypersomnia, leaden paralysis, sensitivity to rejection.	MAOIs, SSRIs, psychotherapy.	[13]

QSAR models link chemical structures with biological effects, aiding the improvement of drugs' therapeutic and pharmacokinetic qualities. Enhanced by machine learning, QSAR models now analyze vast data sets to reveal intricate structure-activity connections [14]. While in-silico drug discovery holds promise, challenges like the accuracy of biological models and the necessity for computational predictions' validation via lab and animal tests persist. Nonetheless, merging in-silico and experimental techniques is accelerating antidepressant research advancements.

ANTIDEPRESSANTS AS MEDICATIONS

Antidepressants, primarily used for major depressive disorder (MDD) and other mood disorders, modify brain neurotransmitter levels, key in mood regulation. Imbalances in neurotransmitters like serotonin, norepinephrine, and dopamine are linked to depression symptoms. SSRIs, such as fluoxetine and sertraline, increase serotonin availability by

blocking its reuptake, aiding symptom relief [15]. SNRIs like venlafaxine and duloxetine target both serotonin and norepinephrine, enhancing their levels, and are effective for various depression forms [14]. Older TCAs and MAOIs also increase neurotransmitter levels but have more side effects, yet are useful for some unresponsive to newer drugs [16].

The monoamine hypothesis, suggesting monoamine neurotransmitter deficiency underlies depression, is supported by antidepressants' effectiveness in elevating these neurotransmitters. However, the delayed antidepressant efficacy indicates that immediate neurotransmitter increases don't directly translate to symptom relief [17]. Recent neuroscience advances highlight other systems like glutamate in depression, with ketamine's rapid-acting properties pointing to new treatment avenues beyond monoamines [18].

TABLE 2. AN OVERVIEW OF THE DIVERSE LANDSCAPE OF ANTIDEPRESSANT MEDICATIONS, EACH WITH ITS UNIQUE PROFILE SUITED TO DIFFERENT CLINICAL NEEDS AND PATIENT PREFERENCES. WHILE EFFICACY IS A CRUCIAL CONSIDERATION, THE CHOICE OF AN ANTIDEPRESSANT OFTEN ALSO DEPENDS ON ITS SIDE EFFECT PROFILE, THE PATIENT'S MEDICAL HISTORY, AND POTENTIAL DRUG INTERACTIONS

Class	**Mechanism of Action**	**Common Examples**	**Primary Uses**	**Potential Side Effects**	**References**
SSRIs (Selective Serotonin Reuptake Inhibitors)	Inhibit serotonin reuptake, increasing its availability in the synaptic cleft.	Fluoxetine (Prozac), Sertraline (Zoloft), Citalopram (Celexa)	Major Depressive Disorder, Anxiety Disorders	Nausea, Headaches, Sexual Dysfunction	[15]
SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)	Inhibit reuptake of serotonin and norepinephrine, increasing their levels.	Venlafaxine (Effexor), Duloxetine (Cymbalta)	Major Depressive Disorder, Anxiety Disorders, Chronic Pain	Increased Blood Pressure, Sweating, Insomnia	[19]
TCAs (Tricyclic Antidepressants)	Block reuptake of norepinephrine and serotonin, also affecting other neurotransmitter systems.	Amitriptyline (Elavil), Nortriptyline (Pamelor)	Major Depressive Disorder, Neuropathic Pain	Dry Mouth, Blurred Vision, Cardiotoxicity	[16]
MAOIs (Monoamine Oxidase Inhibitors)	Inhibit monoamine oxidase enzyme, reducing breakdown of serotonin, norepinephrine, and dopamine.	Phenelzine (Nardil), Tranylcypromine (Parnate)	Treatment-Resistant Depression	Dietary Restrictions, Hypertensive Crisis	[17]

While antidepressants have been a mainstay in treating depression, they are not universally effective. Approximately one-third of patients do not respond adequately to treatment, a condition known as treatment-resistant depression (TRD). The variability in individual response highlights the need for personalized medicine approaches in psychiatry, possibly guided by genetic, biomarker, or neuroimaging data to predict treatment response [2].

Furthermore, the delayed onset of action of most antidepressants and their side effects often discourage adherence, underscoring the need for the development of new agents with faster onset and fewer adverse effects. The recent approval of esketamine, a nasal spray formulation of ketamine's enantiomer, for TRD, represents a significant advancement in offering more rapid relief for those with severe symptoms [20].

CHALLENGES IN ANTIDEPRESSANT DRUG DISCOVERY

Complexities of Depression

Depression's intricacy stems from an interplay of neurological, environmental, and genetic factors, presenting challenges in understanding and treating the disorder effectively. Neurologically, depression correlates with irregularities in brain regions and neurotransmitter systems crucial for mood, cognition, and stress response, like the prefrontal cortex and amygdala. While neurotransmitters such as serotonin and dopamine are central to current treatments, the monoamine hypothesis is deemed reductive. Research is increasingly focusing on neuroplasticity and the role of BDNF, which is vital for neuron health, suggesting that depression might involve neuroplasticity impairments [21].

Environmentally, stressors play a significant role in triggering and exacerbating depression. Life traumas, chronic stress, and socioeconomic factors influence depression's onset and intensity, aligning with the stress-vulnerability model that examines the interaction between external stressors and individual coping abilities [22].

Genetically, depression has a considerable hereditary component, with studies suggesting a 37% heritability rate. However, GWAS indicates that depression's genetic aspect is polygenic, involving numerous genes each with a minor effect, making the genetic basis complex. Furthermore, gene-environment interactions complicate the genetic risk factors for depression [23, 24].

An integrated approach, considering the neurological, environmental, and genetic facets, is essential for a comprehensive understanding of depression. The biopsychosocial model underscores the need to consider biological, psychological, and social elements in depression, advocating for personalized medicine to address the disorder's multifaceted nature. This approach, which customizes treatment to an individual's specific genetic, life experience, and neurobiological profile, offers a promising path forward in navigating the complexities of depression management.

ROLE OF NEUROTRANSMITTERS

Neurotransmitters like serotonin, norepinephrine, and dopamine are pivotal in mood regulation, influencing our emotional states, stress responses, and overall well-being. Their roles are critical for understanding mood disorders such as depression and anxiety.

Serotonin, the "feel-good" neurotransmitter, is key in controlling mood, anxiety, and happiness, with deficiencies linked to mood disorders. It also affects sleep, appetite, and digestion. The effectiveness of SSRIs, which increase serotonin levels in the brain, highlights serotonin's role in mood disorders, showing that boosting serotonergic activity can enhance mood [25].

Norepinephrine, or noradrenaline, is essential for the body's stress response, affecting arousal, alertness, and attention. It boosts heart rate, blood pressure, and blood sugar, energizing the body during stress. Its role in mood regulation is significant, with dysregulation associated with depression. SNRIs, which elevate norepinephrine levels, underscore its importance in mood management [26].

Dopamine, crucial for the brain's reward system, underpins motivation, pleasure, and euphoria, regulating attention, learning, and emotional reactions. Dopamine imbalances contribute to psychiatric and neurodegenerative disorders. In mood regulation, diminished dopaminergic activity is linked to depression symptoms like anhedonia, lack of motivation, and fatigue. Treatments targeting dopamine elevation, especially for atypical depression, aim to mitigate these symptoms [27].

The interaction among serotonin, norepinephrine, and dopamine is intricate, essential for mood stability. These neurotransmitters operate in a synchronized network, each affecting the others' pathways. Imbalances in these neurotransmitters can lead to mood disorders, emphasizing the significance of their balanced regulation for emotional health.

IN-SILICO APPROACHES IN ANTI-DEPRESSANT DRUG DISCOVERY

In-silico approaches have revolutionized antidepressant drug discovery, utilizing computational simulations and models to predict drug-target interactions, thus enhancing the development of new treatments. Molecular docking, a key in-silico technique, forecasts how a drug molecule will bind to a target protein or enzyme, offering insights into its effectiveness and side effects, particularly relevant for molecules acting on mood-related neurotransmitter systems [6].

Pharmacophore modeling, another in-silico strategy, determines the essential molecular features needed for drug-

target interaction, aiding in the design of new compounds that replicate these critical structures [28]. QSAR modeling, which associates chemical structure with biological activity, enables the prediction of new compounds' activity, streamlining the identification of promising drug candidates [29].

Virtual high-throughput screening (vHTS) expedites the drug discovery phase by rapidly evaluating vast compound libraries for potential therapeutic effects, leveraging computational algorithms to filter likely candidates [30]. The integration of machine learning and AI has further refined in-silico methods, allowing for the analysis of extensive datasets to uncover patterns and relationships not evident through conventional techniques. AI algorithms combine various data types, such as genomic and proteomic information, to foresee drug efficacy and safety [31].

Despite their promise, in-silico methods face challenges like the need for precise biological databases and the complexity of accurately simulating biological systems. Nonetheless, blending in-silico and experimental data, coupled with advancements in computational models, is poised to significantly improve antidepressant drug discovery's efficiency and success.

MOLECULAR MODELLING AND SIMULATION

Molecular modeling is crucial in antidepressant discovery, enabling the detailed exploration of drug-target protein interactions. This computational method helps predict small molecule interactions with biological proteins, shedding light on potential therapeutic effects or side effects. Structure-based drug design (SBDD) is central to this approach, utilizing the 3D structures of target proteins from techniques like X-ray crystallography to simulate drug-protein interactions, particularly those affecting mood regulation pathways [32].

Molecular docking, a key technique in molecular modeling, predicts how drug molecules bind to protein targets, offering insights into the interaction's strength and specificity. This is vital for creating drugs that precisely influence target proteins involved in depression's neurotransmitter pathways [33]. Molecular dynamics (MD) simulations add another dimension by examining the dynamic interactions between drugs and proteins over time, considering their flexibility. This aids in understanding the impact of protein conformational changes on drug efficacy, guiding the development of more effective antidepressants [34].

Pharmacophore modeling focuses on identifying drug molecules' essential features responsible for their biological activity. This helps design new compounds with similar interactions with target proteins, useful in generating diverse lead compounds for further testing [35]. The synergy of molecular modeling with high-throughput screening and bioinformatics has expedited antidepressant drug discovery, allowing for the rational design of drugs with enhanced potency, selectivity, and fewer side effects by providing a molecular-level understanding of drug-target interactions.

OPTIMIZING DRUG DESIGN AND EFFICACY

In-silico techniques have transformed antidepressant drug discovery, offering advanced tools to enhance drug design and efficacy. These computational strategies enable the simulation and prediction of drug molecule behaviors, including interactions with biological targets and potential side effects, thereby streamlining drug development.

Molecular docking, a key in-silico method, predicts the optimal binding of drug molecules to target proteins, crucial for identifying compounds that influence neurotransmitter transporters involved in depression. This aids in refining drug structures for better affinity and specificity, minimizing unwanted effects [6].

QSAR modeling correlates chemical structures with biological activity, allowing for the prediction of new compounds' properties based on similar molecules' activities. This identifies essential features for antidepressant activity, guiding the development of more effective drugs [29].

Pharmacophore modeling determines the necessary molecular features for interaction with biological targets, aiding in designing compounds that emulate these interactions, especially valuable when the target protein's structure is unknown [28].

In-silico approaches also include ADMET profile predictions, simulating how drugs are absorbed, metabolized, and excreted, optimizing candidates for efficacy and safety before clinical trials [36].

Integrating machine learning and AI with traditional in-silico methods enhances drug design by analyzing large datasets to identify complex patterns, predicting drug efficacy and side effects, and tailoring treatments to individual patient profiles [31].

In-silico methods are crucial in creating novel antidepressants with improved therapeutic profiles, reducing traditional drug development's time and cost. With ongoing advancements, these technologies promise to expedite effective treatment discoveries for depression and other mood disorders.

TABLE 3. The diversity of in-silico approaches that are revolutionizing antidepressant drug discovery by providing insights into drug-target interactions, predicting drug behavior, and facilitating the design of novel therapeutic compounDS

TARGET-BASED DRUG DESIGN

Target-based drug design (TBDD) is a cornerstone in creating new antidepressants, aimed at designing drugs that specifically target biological mechanisms involved in depression. Unlike traditional methods relying on chance discoveries, TBDD focuses on receptors, enzymes, or ion channels key to mood regulation and depression's neural basis.

The first step in TBDD is identifying targets within neurotransmitter systems like serotonin and dopamine, or other areas such as neurotrophic factors and neuroinflammation pathways, expanded by advances in neurobiology and genetics. High-throughput and genetic screenings, including GWAS, are instrumental in finding new targets for treatment [37].

Following target identification, molecular modeling and simulations, using techniques like X-ray crystallography, help understand the target's structure, aiding in designing high-affinity, specific molecules. Molecular docking predicts drug-target interactions, optimizing drug efficacy and minimizing side effects [6]. TBDD employs SBDD, using the target's 3D structure to guide molecule design, identifying key binding sites for therapeutic activity. This method has been effective in developing inhibitors for enzymes and neurotransmitter reuptake transporters crucial for mood regulation [32]. Lead compounds identified are then optimized for properties like potency and safety through QSAR modeling and pharmacophore mapping, enhancing their therapeutic profile [36]. Before clinical trials, these leads undergo in vitro and in vivo validation to confirm their biological activity and potential antidepressant effects, despite the challenges in replicating psychiatric conditions in animal models [38].

Despite TBDD's promise, antidepressant development faces challenges due to depression's complexity and individual treatment response variability. Future TBDD efforts may explore polypharmacology and systems biology to understand mood regulation networks and personalized medicine, using genetic and biomarker data to tailor treatments to individual patient needs.

In-Silico Approach	Application in Antidepressant Drug Discovery	Benefits	References
Molecular Docking	Predicts how potential antidepressant compounds bind to target proteins, such as neurotransmitter receptors or transporters.	Facilitates the identification and optimization of compounds with high affinity and specificity for target proteins.	[6]
QSAR Modeling	Correlates chemical structures with biological activity to predict the pharmacological properties of new compounds.	Enables the design of compounds with desired antidepressant activity by identifying crucial molecular features.	[29]
Pharmacophore Modeling	Identifies the essential features required for a molecule to interact with a biological target, aiding in the design of new drug candidates.	Guides the development of novel antidepressants by elucidating key drug-target interactions.	[28]
Molecular Dynamics Simulations	Simulates the dynamic behavior of drug-protein complexes over time, taking into account the flexibility of both the drug and the target.	Provides insights into the stability and conformational changes of drug-target interactions, enhancing drug design.	[34]
Virtual High-Throughput Screening (vHTS)	Rapidly evaluates large libraries of compounds against potential targets to identify promising candidates.	Accelerates the initial phase of drug discovery by narrowing down vast compound libraries to those most likely to exhibit antidepressant effects.	[30]
ADMET Prediction	Predicts the Absorption, Distribution, Metabolism, Excretion, and Toxicity profiles of potential antidepressants.	Optimizes drug candidates for better efficacy and safety profiles by simulating their behavior in the body.	[36]
Machine Learning and AI	Integrates and analyzes large datasets to uncover patterns and relationships that inform drug design, including genomic, proteomic, and pharmacological data.	Enhances drug discovery by identifying novel targets, predicting drug efficacy, and personalizing treatments based on individual patient data.	[31]

INFLAMMATION AND IMMUNE SYSTEM MODULATION

Emerging research highlights inflammation's role in depression, revealing how proinflammatory cytokines affect neurotransmitter metabolism, neuroendocrine functions, and neuronal plasticity. This understanding has prompted

investigations into anti-inflammatory agents as antidepressants, with studies on cytokine inhibitors like infliximab showing potential in treating depression associated with high inflammation levels [39].

The endocannabinoid system, pivotal in mood and stress regulation, presents a new avenue for antidepressant discovery. Modulating this system through receptor agonists or inhibitors of endocannabinoid breakdown has shown antidepressant potential in early studies, suggesting enhanced endocannabinoid signaling as a novel treatment strategy [40].

Sigma-1 receptors, endoplasmic reticulum proteins involved in neurotransmission and neuroplasticity, are linked to depression and other mental disorders. Targeting these receptors has demonstrated antidepressant efficacy in preclinical models, indicating a unique antidepressant mechanism [41].

Furthermore, addressing circadian rhythm disruptions, often associated with depression, offers a novel therapeutic angle. Drugs like agomelatine, which act on melatonergic receptors and 5-HT2C antagonists, can resynchronize circadian rhythms, improving mood and sleep in depressive patients [42].

The pursuit of new antidepressant mechanisms is expanding treatment possibilities, especially for patients unresponsive to conventional therapies. By exploring various facets of depression's neurobiology, including inflammatory pathways, the endocannabinoid system, sigma-1 receptors, and circadian rhythm modulation, researchers aim to develop more efficacious, rapid-acting, and safer antidepressant options.

CONCLUSION

The integration of in-silico methods into antidepressant research has revolutionized the field, enabling a deeper understanding of depression and fostering the creation of more effective, personalized therapies. These computational techniques, utilizing high-throughput data analysis, molecular modeling, and simulations, have accelerated the discovery of new therapeutic targets and the optimization of drug candidates, streamlining the prediction of their efficacy and safety. In-silico strategies like molecular docking, QSAR modeling, and pharmacophore mapping provide detailed insights into drug-target interactions, facilitating drug design with enhanced pharmacological properties and reducing dependency on trial-and-error in early development stages.

These methods have also been pivotal in identifying new action mechanisms for antidepressants beyond traditional treatments, discovering targets in glutamatergic, neurotrophic, and inflammatory pathways, thus broadening treatment options for non-responding patients. Additionally, the predictive capability of in-silico approaches extends to assessing drug-like qualities and ADMET profiles early on, crucial for ensuring favorable pharmacokinetics and safety.

The synergy of machine learning and AI with computational techniques has further advanced complex data analysis, aiding in biomarker identification, patient stratification, and personalized treatment approaches, moving towards precision psychiatry. In-silico approaches are now key in antidepressant drug discovery, offering efficient, targeted pathways to new treatments, and hold significant potential to transform antidepressant therapy and mental health care, heralding a new chapter in combating depression.

REFERENCES

1. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

2. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., ... & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917.

3. Langdon, S. R. (2019). In-silico drug discovery: From target identification through lead optimization. ChemBioChem, 20(9), 1061-1070.

4. Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2019). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nature Medicine, 22(3), 238-249.

5. Autry, A. E., & Monteggia, L. M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacological Reviews, 64(2), 238-258.

6. Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery, 3(11), 935-949.

7. Klein, D. N., Shankman, S. A., & Rose, S. (2006). Dysthymic disorder and double depression: Prediction of 10-year course trajectories and outcomes. Journal of Psychiatric Research, 40(5), 408-415.

8. Miklowitz, D. J., & Gitlin, M. J. (2016). The Bipolar Disorder Survival Guide: What You and Your Family Need to Know. New York, NY: Guilford Press.

9. Rosenthal, N. E. (2005). Winter Blues: Everything You Need to Know to Beat Seasonal Affective Disorder. New York, NY: Guilford Press.

10. Stewart, D. E., & Vigod, S. (2016). Postpartum Depression. New England Journal of Medicine, 375, 2177-2186.

11. Epperson, C. N., Steiner, M., Hartlage, S. A., Eriksson, E., Schmidt, P. J., Jones, I., & Yonkers, K. A. (2012). Premenstrual Dysphoric Disorder: Evidence for a new category for DSM-5. American Journal of Psychiatry, 169(5), 465-475.

12. Rothschild, A. J. (2003). Psychotic depression: A review of therapeutic approaches. Psychiatric Clinics of North America, 26(2), 289-309.

13. Henkel, V., Bussfeld, P., Möller, H. J., & Hegerl, U. (2004). Cognitive-behavioural theories of helplessness/hopelessness: Valid models of depression? European Archives of Psychiatry and Clinical Neuroscience, 254(4), 256-264.
14. Polishchuk, P. G. (2017). Interpretation of quantitative structure-activity relationship models: Past, present, and future. Journal of Cheminformatics, 9(1), 62.
15. Stahl, S. M. (2008). Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press.
16. Katzung, B. G. (2017). Basic & Clinical Pharmacology. McGraw-Hill Education.
17. Belmaker, R. H., & Agam, G. (2008). Major depressive disorder. New England Journal of Medicine, 358(1), 55-68.
18. Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2017). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery, 7(5), 426-437.
19. Harvey, A. T. (2015). The role of serotonin and norepinephrine in depression and the therapeutic effects of serotonergic and noradrenergic antidepressants. Journal of Clinical Psychiatry, 76(4), e520-e528.
20. FDA. (2019). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. [FDA News Release].
21. Duman, R. S., Heninger, G. R., & Nestler, E. J. (1997). A molecular and cellular theory of depression. Archives of General Psychiatry, 54(7), 597-606.
22. Kendler, K. S., Karkowski, L. M., & Prescott, C. A. (1999). Causal relationship between stressful life events and the onset of major depression. American Journal of Psychiatry, 156(6), 837-841.
23. Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000). Genetic epidemiology of major depression: Review and meta-analysis. American Journal of Psychiatry, 157(10), 1552-1562.
24. Uher, R. (2014). Gene-environment interactions in common mental disorders: an update and strategy for a genome-wide search. Social Psychiatry and Psychiatric Epidemiology, 49(1), 3-14.
25. Frazer, A., & Benmansour, S. (2002). Delayed pharmacological effects of antidepressants. Molecular Psychiatry, 7(Suppl 1), S23-S28.
26. Delgado, P. L., & Moreno, F. A. (2000). Role of norepinephrine in depression. Journal of Clinical Psychiatry, 61(Suppl 1), 5-12.
27. Nestler, E. J., & Carlezon, W. A. (2006). The mesolimbic dopamine reward circuit in depression. Biological Psychiatry, 59(12), 1151-1159.
28. Langer, T., & Hoffmann, R. D. (2006). Pharmacophores and Pharmacophore Searches. Wiley-VCH.
29. Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., ... & Tropsha, A. (2014). QSAR modeling: where have you been? Where are you going to? Journal of Medicinal Chemistry, 57(12), 4977-5010.
30. Shoichet, B. K. (2004). Virtual screening of chemical libraries. Nature, 432(7019), 862-865.
31. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., ... & Chambers, J. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463-477.
32. Andersen, J. (2003). Structural and computational chemistry in the discovery of selective monoamine oxidase inhibitors. Current Medicinal Chemistry, 10(14), 1295-1312.
33. Kuntz, I. D., Blaney, J. M., Oatley, S. J., Langridge, R., & Ferrin, T. E. (1992). A geometric approach to macromolecule-ligand interactions. Journal of Molecular Biology, 161(2), 269-288.
34. Karplus, M., & McCammon, J. A. (2002). Molecular dynamics simulations of biomolecules. Nature Structural Biology, 9(9), 646-652.
35. Guner, O. F. (2000). Pharmacophore Perception, Development, and use in Drug Design. International University Line.
36. Van De Waterbeemd, H., & Gifford, E. (2003). ADMET in silico modelling: Towards prediction paradise? Nature Reviews Drug Discovery, 2(3), 192-204.
38. Cryan, J. F., & Holmes, A. (2005). The ascent of mouse: advances in modelling human depression and anxiety. Nature Reviews Drug Discovery, 4(9), 775-790.
39. Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., ... & Miller, A. H. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry, 70(1), 31-41.
40. Hill, M. N., & Gorzalka, B. B. (2005). Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. European Neuropsychopharmacology, 15(6), 593-599.
41. Hayashi, T., & Su, T. P. (2007). Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca^{2+} signaling and cell survival. Cell, 131(3), 596-610.
37. Pittenger, C., & Duman, R. S. (2008). Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology, 33(1), 88-109.
42. Quera-Salva, M. A., Vanier, B., Laredo, J., Hartley, S., Chapotot, F., Moulin, C., ... & Lofaso, F. (2010). Major depressive disorder, sleep EEG and agomelatine: an open-label study. International Journal of Neuropsychopharmacology, 13(5), 663-671.